Effects of “Yunnan Dengzhanhua Capsule”on Renal Function and Expressions of Tumor Growth Factor-β_1 and Plasminogen Activator Inhibitor-1 in Rats with Chronic Renal Failure

Objective: To study the effects ofYunnan Dengzhanhua Capsuleon renal function and renal fibrosis in rats with chronic renal failure( CRF). Methods: Sixty SD rats were randomly divided into normal control group,model group,Benazepril group andYunnan Dengzhanhua Capsulegroup,with 15 rats in each group. The CRF models were established by5 /6 nephrectomized. The Benazepril group was treated with Benazepril( 0. 29 mg /100 g) by intragastric administration. TheYunnan Dengzhanhua Capsulegroup was treated withYunnan Dengzhanhua Capsule( 0.3 g/100 g) intragastrically. The normal control group and model group were treated with the same dose of normal saline( NS) intragastrically,with the course of 12 weeks. We detected the serum creatinine( Scr),blood urea nitrogen,24 h urinary protein before and after treatment.Expressions of TGF-β1and PAI-1 were determined by RT-PCR method after treatment. Results: Compared with the model group,the serum creatinine( Scr),blood urea nitrogen and 24 h urinary protein in theYunnan Dengzhanhua Capsulegroup and Benazepril group were decreased markedly( P 0. 05),and the Scr and 24 h urinary protein in theYunnan Dengzhanhua Capsulegroup were lower than that of the Benazepril group( P 0. 05). Expressions of TGF-β1and PAI-1 in theYunnan Dengzhanhua Capsulegroup and Benazepril group were lower than that of the model group,with significant difference between them( P 0. 05),and the expressions of TGF-β1and PAI in theYunnan Dengzhanhua Capsulegroup were lower than that of the Benazepril group( P 0. 05). Conclusion: Yunnan Dengzhanhua Capsulecan improve renal function and inhibit renal fibrosis in CRF rats.